Safeguard Scientifics, Inc. Stock Price, News & Analysis

Rockwell Medical, Inc. (NASDAQ: RMTI) has appointed Heather Hunter as Senior Vice President and Chief Corporate Affairs Officer. Heather brings over 20 years of experience in executive leadership and investor relations, aiming to enhance the company's communications and branding strategies. CEO Mark Strobeck expressed confidence in Heather's capability to drive shareholder value and facilitate profitability as the company expands its product offerings in the healthcare market. Rockwell Medical focuses on products for patients with blood disorders and kidney diseases, including the development of its proprietary Ferric Pyrophosphate Citrate technology.

Safeguard Scientifics, Inc. (NYSE:SFE) reported mixed financial results for Q2 2022. The company achieved net income of $0.5 million ($0.03 per share) compared to a net loss of $0.3 million in Q2 2021. However, for the six months ended June 30, 2022, it reported a net loss of $6.2 million ($0.38 per share), contrasting with net income of $17.3 million in the same period last year. The aggregate revenues for its companies reached $145 million, up 14.1% year-over-year. Safeguard continues to manage costs effectively, with general and administrative expenses down 45% year-over-year.

Safeguard Scientifics (NYSE:SFE) plans to release its second quarter financial results on August 11, 2022, post-market close. A conference call will be held at 5:00 pm ET to discuss these results, featuring CEO Eric C. Salzman and CFO Mark A. Herndon. Interested participants are encouraged to register 10-15 minutes before the call. Safeguard is focusing on maximizing shareholder value through strategic monetization of its ownership interests over the coming years. The webcast will be available for replay after the event.

Safeguard Scientifics, Inc. (NYSE:SFE) reported a net loss of $6.7 million, or $0.40 per share, for Q1 2022, compared to a net income of $17.6 million, or $0.84 per share in Q1 2021. The company repurchased 147,795 shares for $0.8 million during the quarter, and an additional $0.4 million post-quarter. Aggregate revenue from nine companies was $141 million, up 16.2% year-over-year. Safeguard aims to manage corporate expenses tightly, targeting $3.5 to $4 million for the year, and anticipates sharing strategic updates in Q3 2022.

Safeguard Scientifics (NYSE:SFE) will release its first quarter financial results for 2022 on May 5, after market close. The company will hold a conference call at 5:00 PM ET that same day, featuring CEO Eric C. Salzman and CFO Mark A. Herndon. This call will discuss the Q1 results, followed by a Q&A session. Safeguard is focused on maximizing shareholder value through strategic business operations. Interested parties can join via a dial-in number or a webcast link that will also offer a replay after the event.

Safeguard Scientifics, Inc. (NYSE:SFE) announced a new share repurchase program of $3 million, set to be completed within 2022. This program replaces a previous $6 million plan, which repurchased 236,159 shares at an average cost of $6.94 per share. The company engaged Houlihan Lokey for strategic alternatives, indicating a potential transaction may affect stock value. Year-to-date deployments total $3.4 million against a full-year estimate of $5-9 million. CEO Eric C. Salzman stated the current share price does not reflect the company's fair market value.

Safeguard Scientifics reported a net income of $27 million for 2021, a recovery from a $37.6 million loss in 2020. Cash proceeds of $60.8 million were generated from exits, with $39 million spent on share repurchases. The company noted a 7.1% decline in trailing revenues, totaling $246 million. Operating costs were reduced, with general and administrative expenses decreasing to $7.2 million. For 2022, a target of $5 million to $9 million in follow-on deployments is expected. A financial advisor has been engaged to explore strategic options for maximizing shareholder value.

Safeguard Scientifics, Inc. (NYSE:SFE) will announce its financial results for the full year and fourth quarter ending December 31, 2021, on March 9, 2022, after the market closes. A conference call is scheduled for the same day at 5:00 pm ET, featuring Chief Executive Officer Eric C. Salzman and Chief Financial Officer Mark A. Herndon discussing the results followed by a Q&A session. The call can be accessed at 844-200-6205 with access code 544056, while a webcast will be available through their investor relations site.

Safeguard Scientifics (NYSE:SFE) completed a $39 million self-tender offer, repurchasing 4.3 million shares at $9.00 each. The company reported a net income of $18.3 million ($0.88 per share) for Q3 2021, a significant turnaround from a net loss of $4.3 million in Q3 2020. However, trailing twelve-month revenues decreased by 11% to $245 million. Cash and equivalents stood at $64.2 million, while the carrying value of ownership interests was $36.3 million. Looking forward, Safeguard has deployed $2.7 million year-to-date and expects no significant deployments for the remainder of 2021.